The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
10 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,846,866 in first-year total cost, median $224,960.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-H (11)]4
- Special Emphasis Panel[ZRG1 ETTN-P (13)]3
- Special Emphasis Panel[ZRG1 ETTN-C (10)]1
- Special Emphasis Panel[ZRG1 RPHB-Y (12)]1
- Special Emphasis Panel[ZRG1 SBIB-T (10)]1
Most frequent institutions
- ARCHER PHARMACEUTICALS, INC.1
- CORTICOMETRICS, LLC1
- DTX PHARMA, LLC1
- MASSACHUSETTS GENERAL HOSPITAL1
- NEURODON LLC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Personalized anesthetic brain monitoring: Developing novel systems, sensors, and algorithms for aging, dementia, and Alzheimers disease patients1R42AG066325-01 | LE MAU, TUANPURDON, PATRICK L. | PASCALL SYSTEMS, INCORPORATED, MA | $449,671 | ZRG1 |
| 2020 | Developing EV surface proteins as biosignatures for Alzheimer's disease (AD)1R41AG066328-01 | TAO, W. ANDY | TYMORA ANALYTICAL OPERATIONS, LLC, IN | $244,909 | ZRG1 |
| 2020 | Reversal of Tau Pathology with MSUT2 siRNA Conjugates1R41AG063616-01A1 | KRAEMER, BRIAN C.SUCKOW, ARTHUR THOMAS | DTX PHARMA, LLC, CA | $213,027 | ZRG1 |
| 2019 | Fluorescence lifetime platform to discover small-molecule inhibitors of tau and alpha-synuclein oligomerization.1R43AG063675-01A1 | THOMAS, JENNIFER JEWELL | PHOTONIC PHARMA, LLC, MN | $593,889 | ZRG1 |
| 2019 | Unbiased longitudinal neuromorphometry for clinical decision support1R42AG062026-01A1 | FISCHL, BRUCEWIGHTON, PAUL | CORTICOMETRICS, LLC, MA | $224,843 | ZRG1 |
| 2019 | Testing the feasibility of Rendever with older adults with cognitive impairments and their adult children.1R41AG063640-01A1 | AFIFI, TAMARA DAWNCOLLINS, NANCY LEERAND, KYLE PATRICK | RENDEVER, INC., MA | $146,821 | ZRG1 |
| 2018 | Production and quality analysis of clinical drug for a novel CNS protein kinase inhibitor therapeutic candidate1R42AG062095-01 | WATTERSON, DANIEL MARTIN | NEUROKINE THERAPEUTICS, LLC, NY | $504,907 | ZRG1 |
| 2018 | Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer’s disease1R41AG062001-01 | DAHL, RUSSELL | NEURODON LLC, IN | $225,000 | ZRG1 |
| 2018 | Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.1R42AG062063-01 | BLOUGH, BRUCE EMULLAN, MICHAELPARIS, DANIEL | ARCHER PHARMACEUTICALS, INC., FL | $224,920 | ZRG1 |
| 2018 | Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD1R41AG062130-01 | ALBERS, MARK W | MASSACHUSETTS GENERAL HOSPITAL, MA | $18,879 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.